July’s glaucoma news included updates on trial enrollments and study results.
Here are the top five glaucoma-related articles on Healio.com/OSN during the month:
FDA accepts application for Bimatoprost Sustained-Release
Data supporting the application from the two phase 3 ARTEMIS trials showed Bimatoprost SR reduced IOP by 30% over 12 weeks. In addition, more than 80% of patients were treatment-free after three Bimatoprost SR treatments and did not require further treatment for IOP control for at least 12 months. Read more.
iSTAR’s MINIject shows positive 18-month results
Uncategorized